Current status of drugs targeting PDGF/PDGFR

Drug Discov Today. 2024 Apr 23:103989. doi: 10.1016/j.drudis.2024.103989. Online ahead of print.ABSTRACTAs an important proangiogenic factor, platelet-derived growth factor (PDGF) and its receptor PDGFR are highly expressed in a variety of tumors, fibrosis, cardiovascular and neurodegenerative diseases. Targeting the PDGF/PDGFR pathway is therefore a promising therapeutic strategy. At present, a variety of PDGF/PDGFR targeted drugs with potential therapeutic effects have been developed, mainly including PDGF agonists, inhibitors targeting PDGFR and proteolysis targeting chimera (PROTACs). This review clarifies the structure, biological function and disease correlation of PDGF and PDGFR, and it discusses the current status of PDGFR-targeted drugs, so as to provide a reference for subsequent research.PMID:38663580 | DOI:10.1016/j.drudis.2024.103989
Source: Drug Discovery Today - Category: Drugs & Pharmacology Authors: Source Type: research